HCC Biomarkers

AFP-L3 and DCP

HCC Biomarkers Resources


Doctor Robert G. Gish, a world renowned hepatologist, speaks about the importance of including biomarkers for HCC risk assessment in liver cancer surveillance programs and proposes his current liver surveillance algorithm as a model. To view the presentation:

Study results support the combined use of AFP-L3 and DCP in surveillance. Researchers from Japan and UK presented study results in a poster at The Liver Meeting® 2013.

Study results support the use of biomarkers AFP-L3 and DCP for risk assessment in Surveillance. Researchers from Thomas Jefferson University Hospital, Philadelphia, PA, presented study results in a poster at the 2013 Digestive Diseases Week (DDW) Conference, supporting the use of serum biomarkers AFP, AFP-L3 and DCP for Risk Assessment in Surveillance of Patients at Risk for HCC development.


HCC biomarkers general information

How to manage patients at-risk for HCC development

How to order AFP-L3 and DCP tests